# US 2006/0067927 A1 · Methods and compositions related to the modulation of intercellular junctions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0067927 A1
- Document ID: US20060067927A1
- Status: Published application
- Kind: A1
- Application number: 11/171,490
- Filed: 2005-06-29
- Published: 2006-03-30
- Earliest claimed: 2004-06-29
- Assignees: Massachusetts Institute of Technology
- Inventors: Aarthi Chandrasekaran; Shiladitya Sengupta; David Berry; Kristine Holley; Ganlin Zhao; Ram Sasisekharan
- Web page: https://patentgrep.com/patent/US20060067927A1

## CPC

- A61K 38/51: Lyases (4)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)
- A61K 31/727: Heparin; Heparan
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 38/45: Transferases (2)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods provided can be used to facilitate the delivery of biologically active molecules.

## Claims

### Claim 1

A method for transiently disrupting intercellular junctions in a subject, comprising:
administering to a subject not ordinarily in need thereof via a nonpulmonary route an intercellular junction disruption agent in an amount effective to transiently disrupt intercellular junctions, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both.

### Claim at position 2

2-14. (canceled)

### Claim 15

A method for enhancing the delivery of a biologically active molecule through a cell barrier, comprising:
administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the intercellular junction disruption agent is administered prior to or after the administration of the biologically active molecule, and wherein the delivery of the biologically active molecule is enhanced.

### Claim at position 4

-34. (canceled)

### Claim 35

A method for treating a subject, comprising:
administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the subject has an infection or an infection related disorder, and wherein the intercellular junction disruption agent is a heparan sulfate-like glycosaminoglycan, a heparin-like glycosaminoglycan or an enzyme that degrades heparan sulfate-like glycosaminoglycans or heparin-like glycosaminoglycans or some combination thereof.

### Claim at position 6

-42. (canceled)

### Claim 43

A method for treating a subject, comprising:
administering to the subject a glycosaminoglycan-degrading enzyme and a biologically active molecule, wherein the subject has a respiratory disorder.

### Claim at position 8

-53. (canceled)

### Claim 54

A method for treating a subject, comprising:
administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the subject has an ocular disorder, an immunologic disorder that is not rheumatoid arthritis or psoriasis, or a dermatologic disorder that is not psoriasis, and wherein when the subject has an ocular disorder, the intercellular junction disruption agent is a chondroitin sulfate glycosaminoglycan or a chondroitinase.

### Claim at position 10

-76. (canceled)

### Claim 77

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:
administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is linked to a molecule that targets the blood-brain barrier.

### Claim at position 12

-81. (canceled)

### Claim 82

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:
administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is administered via the internal carotid artery.

### Claim 83

(canceled)

### Claim 84

A method for enhancing the delivery of a biologically active molecule through the blood-brain barrier, comprising:
administering to a subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active molecule is an agent for treating a central nervous system disorder, and wherein the delivery of the biologically active molecule is enhanced.

### Claim 85

A method for enhancing the delivery of a biologically active molecule to a subject, comprising:
administering to the subject an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the administration is ocular, via the nasal tract or via the skin, sublingual tissue or gastrointestinal tissue, and wherein the delivery of the biologically active molecule is enhanced.

### Claim at position 17

-94. (canceled)

### Claim 95

A method for enhancing the delivery of a biologically active molecule through the upper or lower respiratory tract in a subject, comprising:
administering to the subject via the upper or lower respiratory tract a glycosaminoglycan-degrading enzyme, and a biologically active molecule.

### Claim at position 19

-166. (canceled)

### Claim 167

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active molecule is an agent for treating central nervous system disorders, and wherein the intercellular junction disruption agent is not a chondroitinase ABC I-generated chondroitin sulfate fragment or chondroitinase ABC I.

### Claim 168

(canceled)

### Claim 169

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active agent is an agent for treating an infection or an infection related disorder, and wherein the intercellular junction disruption agent is a heparan sulfate-like glycosaminoglycan, a heparin-like glycosaminoglycan, or an enzyme that degrades heparan sulfate-like glycosaminoglycans or heparin-like glycosaminoglycans or some combination thereof.

### Claim at position 23

-171. (canceled)

### Claim 172

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the biologically active agent is an agent for treating a respiratory disorder, an ocular disorder, an immunologic disorder that is not rheumatoid arthritis or psorasis, or a dermatolozic disorder that is not psoriasis, and wherein when the biologically active agent is an agent for treating an ocular disorder, the intercellular junction disruption agent is a chondroitin sulfate glycosaminoglycan or a chondroitinase.

### Claim at position 25

-178. (canceled)

### Claim 179

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the intercellular junction disruption agent or biologically active molecule is linked to a molecule that targets the blood-brain barrier.

### Claim 180

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, wherein the composition is in a form suitable for administration to the eye, nasal administration, topical administration or sublingual, vaginal or rectal delivery, and wherein the form suitable for nasal administration is a nasal spray, nasal drop or nasal gel, and wherein the form suitable for topical administration is an ointment, lotion, spray, gel, cream, swab, wipe, bandage or patch, and wherein the form suitable for sublingual delivery is a sublingual tablet or oral gel.

### Claim at position 28

-187. (canceled)

### Claim 188

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan-degrading enzyme wherein the composition is in a form suitable for pulmonary delivery, and wherein the form suitable for pulmonary delivery is an inhaler.

### Claim at position 30

-191. (canceled)

### Claim 192

A composition, comprising:
an intercellular junction disruption agent and a biologically active molecule, wherein the intercellular junction disruption agent is a glycosaminoglycan, a glycosaminoglycan-degrading enzyme or both, and wherein the composition is in an enteric tablet or capsule.
